Skip to main content

Clindamycin topical Disease Interactions

There is 1 disease interaction with clindamycin topical.


Topical clindamycin (applies to clindamycin topical) colitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious)

Clindamycin may be systemically absorbed when applied to the skin or mucosal membranes. Pseudomembranous colitis has been reported with systemically as well as topically administered clindamycin and may range in severity from mild to life-threatening, with an onset of up to several weeks following cessation of therapy. The colitis is usually characterized by severe, persistent diarrhea and severe abdominal cramps, and may be associated with the passage of blood and mucus. Therapy with topical clindamycin should be administered cautiously in patients with a history of gastrointestinal diseases, particularly colitis. There is some evidence that pseudomembranous colitis, if it occurs, may run a more severe course in these patients and that it may be associated with flares in their underlying disease activity. Certain products may be contraindicated by the manufacturer, and prescribers are advised to consult the package labeling. Clindamycin should be discontinued if significant diarrhea occurs during therapy. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. A large bowel endoscopy may be considered to establish a definitive diagnosis in cases of severe diarrhea.


  1. Leigh DA, Simmons K, Williams S (1980) "Gastrointestinal side effects following clindamycin and lincomycin treatment: a follow up study." J Antimicrob Chemother, 6, p. 639-45
  2. Davies J, Beck E (1981) "Recurrent colitis following antibiotic-associated pseudomembranous colitis." Postgrad Med J, 57, p. 599-601
  3. Milstone EB, McDonald AJ, Scholhamer CF Jr (1981) "Pseudomembranous colitis after topical application of clindamycin." Arch Dermatol, 117, p. 154-5
  4. Cone JB, Wetzel W (1982) "Toxic megacolon secondary to pseudomembranous colitis." Dis Colon Rectum, 25, p. 478-82
  5. Parry MF, Rha CK (1986) "Pseudomembranous colitis caused by topical clindamycin phosphate." Arch Dermatol, 122, p. 583-4
  6. Van Ness MM, Cattau EL Jr (1987) "Fulminant colitis complicating antibiotic-associated pseudomembranous colitis: case report and review of the clinical manifestations and treatment." Am J Gastroenterol, 82, p. 374-7
  7. Voron DA (1978) "Systemic absorption of topical clindamycin." Arch Dermatol, 114, p. 798
  8. Siegle RJ, Fekety R, Sarbone PD, Finch RN, Deery HG, Voorhees JJ (1986) "Effects of topical clindamycin on intestinal microflora in patients with acne." J Am Acad Dermatol, 15, p. 180-5
  9. Fisher AA (1983) "Adverse reactions to topical clindamycin, erythromycin and tetracycline." Cutis, 32, 415,419,424,428
  10. Borglund E, Hagermark O, Nord CE (1984) "Impact of topical clindamycin and systemic tetracycline on the skin and colon microflora in patients with acne vulgaris." Scand J Infect Dis Suppl, 43, p. 76-81
  11. Gallerani M, Ricci L, Calo G, Manfredini R (1997) "Abdominal pain and diarrhoea caused by topical clindamycin phosphate." Clin Drug Invest, 14, p. 243-5
  12. Trexler MF, Fraser TG, Jones MP (1997) "Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream." Am J Gastroenterol, 92, p. 2112-3
  13. Vikenes K, LundTonnesen S, Schreiner A (1999) "Clostridium difficile-associated diarrhea after short term vaginal administration of clindamycin." Am J Gastroenterol, 94, p. 1969-70
  14. Meadowcroft AM, Diaz PR, Latham GS (1998) "Clostridium difficile toxin-induced colitis after use of clindmycin phosphate vaginal cream." Ann Pharmacother, 32, p. 309-11
View all 14 references

Clindamycin topical drug interactions

There are 12 drug interactions with clindamycin topical.

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.